Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320223 | 0.91 | KIF11 (0.41) | KIF11GPR3CFTRKDM1AMCL1 | |
| SCHEMBL17378834 | 0.83 | KIF11 (0.37) | KIF11CFTRMCL1CES2 | |
| SCHEMBL10697706 | 0.79 | KIF11 (0.45) | KIF11GPR3KDM1AMCL1PTPN7 | |
| SCHEMBL17959909 | 0.77 | TMPRSS4 (0.38) | HSP90AA1 | |
| SCHEMBL31379539 | 0.77 | TMPRSS4 (0.38) | HSP90AA1 | |
| SCHEMBL18894055 | 0.76 | CA9 (0.36) | HSP90AA1 | |
| SCHEMBL16179246 | 0.75 | KIF11 (0.45) | KIF11GPR3KDM1AMCL1PTPN7 | |
| SCHEMBL30945180 | 0.75 | KIF11 (0.45) | KIF11GPR3KDM1AMCL1PTPN7 | |
| SCHEMBL29556547 | 0.75 | KIF11 (0.36) | KIF11GPR3CFTRKDM1A | |
| SCHEMBL16035567 | 0.75 | KIF11 (0.36) | KIF11GPR3CFTRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253755-B1 | NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES | PFIZER (US) | 2020-08-26 | — | — | EP | disclosed |
| CN-107406445-B | Cyclopropylbenzofuranyl pyridopyrazine diones | 辉瑞公司 | 2019-12-24 | — | — | CN | disclosed |
| US-9765073-B2 | Cyclopropabenzofuranyl pyridopyrazinediones | PFIZER INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170096428-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2016125048-A1 | NOVEL CYCLOPROPABENZOFURANYL PYRIDOPYRAZINEDIONES | PFIZER INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160222007-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | PFIZER (US) | 2016-08-04 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| CN-102348697-A | Sulfonamide derivatives | PFIZER LTD | 2012-02-08 | — | — | CN | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| EP-2385938-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-8040476-B2 | Display device and method of producing the same | MITSUBISHI ELECTRIC CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | KIF11 2498/4885GPR3 1300/4885CFTR 995/4885 |
| US-20160222007-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | CYP4B1, RXRB, ADRA2B | KIF11 1259/4885GPR3 1887/4885CFTR 550/4885 |
| US-20170096428-A1 | Novel Cyclopropabenzofuranyl Pyridopyrazinediones | CYP4B1, RXRB, ADRA2B | KIF11 1259/4885GPR3 1887/4885CFTR 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.